North China port sees cargo volume for China-Europe freight trains exceed 5 mln tonnes

19.12.2025

The freight volume of China-Europe freight trains passing through the Erenhot Port — the largest land port between China and Mongolia — has exceeded 5 million tonnes

The freight volume of China-Europe freight trains passing through the Erenhot Port has exceeded 5 million tonnes as of Monday this year, an increase of 22.7 percent year on year, hitting a new record, according to customs authorities.

The port has handled a total of 3,807 China-Europe freight trains this year, transporting 433,600 TEUs of goods, marking year-on-year growth of 17.1 percent and 16.2 percent, respectively, said the China Railway Hohhot Group Co., Ltd.

In 2025, the port added new routes, including routes connecting Wuhu in east China’s Anhui Province with Moscow, Russia, and Datong in north China’s Shanxi Province with Selyatino, Russia.

Customs authorities have also taken a series of measures to enhance efficiency. Currently, the border inspection time for each train has been reduced to about 20 minutes.

As the sole transit port for the «middle corridor» of the China-Europe freight train network, Erenhot currently operates 74 routes connecting over 70 stations across more than 10 countries, including Germany and Poland.

Available after authorization
Sign in
Available after authorization
Sign in
Analytics on topic
Report
18.10.2021
Report
18.10.2021
Benelux countries’ exports to China in 2020: export structure and prospects for modal shift to rail

At the end of 2020, the trade turnover between the Benelux countries and China amounted to about USD 98 billion, of which USD 26.09 billion accounted for exports to China and USD 71.86 billion - for import.

Source: ERAI
Report
20.06.2019
Report
20.06.2019
The Europe Pharmaceutical Industry in Figures
The pharmaceutical industry is a key partner in Europe’s fight against disease, developing new treatments and cures for patients across Europe. It is imperative that Europe remains a competitive destination for medical research and development by maintaining, sustaining and developing a predictable, robust regulatory and innovation-supportive incentives environment.
Source: European Federation of Pharmaceutical Industries and Associations